News
DHTRF
13.52
NaN%
--
DRI Healthcare Earnings Call Signals Stronger Growth Ahead
TipRanks · 6h ago
DRI Healthcare (DHT.UN) Receives a Buy from Stifel Nicolaus
TipRanks · 11/06 17:55
DRI Healthcare Trust price target raised to C$27.50 from C$27 at Stifel
TipRanks · 11/06 17:00
*DRI Healthcare 3Q EPS 84c >DHT.U.T
Dow Jones · 11/04 22:34
*DRI Healthcare 3Q Adj EPS 53c >DHT.U.T
Dow Jones · 11/04 22:34
Press Release: DRI Healthcare Reports Third Quarter 2026 Results
Dow Jones · 11/04 22:00
Press Release: DRI Healthcare Reports Third -2-
Dow Jones · 11/04 22:00
Press Release: DRI Healthcare Reports Third -3-
Dow Jones · 11/04 22:00
Press Release: DRI Healthcare Reports Third -4-
Dow Jones · 11/04 22:00
CIBC Sticks to Its Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 10/30 17:35
DRI Healthcare Schedules Q3 2026 Results Release and Investor Call
TipRanks · 10/14 21:40
Stifel Nicolaus Sticks to Their Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 09/29 14:45
DRI Healthcare Trust price target raised to C$27 from C$26 at Stifel
TipRanks · 09/29 14:45
DRI Healthcare Buys Parkinson’s Drug Royalties After FDA Clears Juvmo
TipRanks · 09/28 14:41
DRI Healthcare: Buy Rating Backed by Tavapadon Royalty Deal, Adding C$1.35 per Unit to Target Price and Enhancing Upside Potential
TipRanks · 09/25 06:55
National Bank Keeps Their Buy Rating on DRI Healthcare (DHT.UN)
TipRanks · 09/24 07:25
DRI Healthcare (DHT.UN) Receives a Buy from Stifel Nicolaus
TipRanks · 09/22 20:05
DRI Healthcare Trust price target raised to C$22 from C$21 at RBC Capital
TipRanks · 09/22 14:35
DRI Healthcare to Spend US$316 Million on Tavapadon Parkinson’s Royalty Deal
TipRanks · 09/21 11:41
Stifel Nicolaus Sticks to Their Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 09/16 16:35
More
Webull provides a variety of real-time DHTRF stock news. You can receive the latest news about DRI HEALTHCARE TRUST through multiple platforms. This information may help you make smarter investment decisions.
About DHTRF
DRI Healthcare Trust is a global pharmaceutical royalty monetization company. The Company's portfolio consists of 29 royalty streams on 23 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. Its Royalty Assets include Ekterly, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Vonjo I, Vonjo II, Xolair, Zejula, Zytiga, and others. The Ekterly is an oral on-demand therapy for treating attacks associated with Hereditary Angioedema (HAE). The Eylea I is a vascular endothelial growth factor inhibitor initially indicated for the treatment of neovascular wet age-related macular degeneration. Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.